HMNC Brain Health Appoints Dr. Bertram Müller-Myhsok as Head of Precision Psychiatry
Retrieved on:
Thursday, February 24, 2022
University, GLOBE, Genetics, Department of Medicine – University of Pamplona, Faculty, Disorder, Head, MDD, LION, Statistical genetics, Bernhard Nocht Institute for Tropical Medicine, Tropical medicine, Habilitation, Max Planck Institute of Psychiatry, Industry, Company, Psychiatry, Ludwig Maximilian University of Munich, Lists of diseases, United Kingdom, Genetic testing, Technical University of Munich, Institute of technology, Human genetics, List of life sciences, Professor, Non-functional testing, VC, Senior, Artificial intelligence, Annemarie, Brain, TRD, Patient, Pontifical Xavierian University Faculty of Medicine, Knowledge, Research, Program, Department, Pharmaceutical industry, Medicine
MUNICH, Germany, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today the appointment of Dr. Bertram Müller-Myhsok as its new Head of Precision Psychiatry, effective March 1, 2022. The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in Munich has signed an additional contract with HMNC Brain Health next to his position at the Max-Planck-Institute. In his new role, Dr. Müller-Myhsok will help the Company to accelerate the development of differentiated treatment options through the combination of novel interventions with precision applications.
Key Points:
- MUNICH, Germany, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (HMNC'' or the Company), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today the appointment of Dr. Bertram Mller-Myhsok as its new Head of Precision Psychiatry, effective March 1, 2022.
- The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in Munich has signed an additional contract with HMNC Brain Health next to his position at the Max-Planck-Institute.
- As Head of Precision Psychiatry, Dr. Mller-Myhsoks decades of experience in human genetics research will allow HMNC Brain Health to advance its work utilizing genetic analyses and artificial intelligence to better detect the underlying genetic or physiological causes of disorders in specific individuals and develop personalized therapies for neuropsychiatric disorders.
- HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates.